Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
The value of testosterone replacement therapy (TRT) for older men is currently a topic of intense debate. While US testosterone prescriptions have tripled in the past decade (9), debate continues over the risks and benefits of TRT. TRT is currently prescribed for older men with either low serum testosterone (T) or low T plus accompanying symptoms of hypogonadism. The normal range for serum testosterone is 300 to 1,000 ng/dl. Serum T ≤ 300 ng/dl is considered to be low, and T ≤ 250 is considered to be frank hypogonadism. Most experts support TRT for older men with frank hypogonadism and symptoms. Treatment for men who simply have low T remains somewhat controversial. TRT is most frequently administered by intramuscular (im) injection of long-acting T esters or transdermally via patch or gel preparations and infrequently via oral administration. TRT produces a number of established benefits in hypogonadal men, including increased muscle mass and strength, decreased fat mass, increased bone mineral density, and improved sexual function, and in some cases those benefits are dose dependent. For example, doses of TRT administered by im injection are typically higher than those administered transdermally, which results in greater musculoskeletal benefits. TRT also produces known risks including development of polycythemia (Hct >50) in 6% of those treated, decrease in HDL, breast tenderness and enlargement, prostate enlargement, increases in serum PSA, and prostate-related events and may cause suppression of the hypothalamic-pituitary-gonadal axis. Importantly, TRT does not increase the risk of prostate cancer. Putative risks include edema and worsening of sleep apnea. Several recent reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report no risk or even benefit. To address the potential CV risks of TRT, we have recently reported via meta-analysis that oral TRT increases CV risk and suggested that the CV risk profile for im TRT may be better than that for oral or transdermal TRT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“However, serum bioT may be estimated from serum total T, SHBG, and albumin by using one of several empirical formulas (57, 86).”
MethodBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 2×
“The Endocrine Society recommends that treatment be individualized, including a determination of whether the patient has primary hypogonadism (primary deficit lies within the testes) or secondary hypogonadism (primary deficit lies outside of the testes) (13).”
BackgroundAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 1×
“(87), in a retrospective study of men with low T and angina who also had undergone angiography, reported a higher CV risk in those who subsequently received T than in those who did not.”
BackgroundBhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757 · cited 1×
“(28), who observed elevated blood markers of bone resorption following combined administration, to older men, of a GnRH agonist and an aromatase inhibitor to inhibit production of T and estradiol, respectively.”
BackgroundIncreased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735 · cited 1×
“(31), reported a greater risk of myocardial infarction in men who had received a prescription for T.”
BackgroundCalof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728 · cited 3×
“(21) showed no significant increase in obstructive sleep apnea with TRT; however, the studies were not conducted with polysomnography.”
BackgroundMethodResultAdverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713 · cited 1×
“Meta-analysis has confirmed three adverse events (AEs) resulting from TRT (21, 29, 34): 1) polycythemia occurring in 6% of participants, 2) an increased number of prostate-related events, and 3) a small reduction in HDL-cholesterol.”
MethodSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · cited 1×
“00 Srinivas-Shankar, 2010 (74) Gel 5/138 2/136 2.”
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582
Page, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566
DHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566 · cited 1×
“None of the four transdermal studies (10, 37, 47, 58) reported a significant increase in 1-RM strength.”
BackgroundSingh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., & Bhasin, S. (2003) · Endocrinology · doi:10.1210/en.2003-0741 · Cited by 555
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Mac, R. P., Lee, M., Yarasheski, K. E., Sinha-Hikim, I., Dzekov, C., Dzekov, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1184 · Cited by 544 · cited 1×
“The benefits with even higher doses of im T (300–600 mg/wk) are even more substantial (upward of 20% increase in 1-RM strength in older men over 20 wk), but the number of adverse events observed at these doses precludes their clinical implementation (14).”
BackgroundFerrando, A. A., Sheffield-Moore, M., Yeckel, C. W., Gilkison, C., Jiang, J., Achacosa, A., Lieberman, S. A., Tipton, K., Wolfe, R. R., & Urban, R. J. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00362.2001 · Cited by 522 · cited 3×
“At low replacement doses, T administration produces muscle protein accretion mainly by preventing protein degradation (30), which is mediated, at least in part, by an increased phosphorylation-induced inactivation of FOXO3a (89).”
BackgroundResultEmmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518 · cited 1×
“09 Emmelot-Vonk, 2008 (26) Oral 8/120 3/117 2.”
Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475 · cited 5×
“In addition, several studies demonstrate that in older hypogonadal men the combination of im T plus finasteride produces musculoskeletal benefits without the prostate enlargement that results from T alone (7, 19).”
BackgroundInfluentialSinha-Hikim, I., Artaza, J., Woodhouse, L., Gonzalez-Cadavid, N., Singh, A. B., Lee, M. I., Storer, T. W., Casaburi, R., Shen, R., & Bhasin, S. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00502.2001 · Cited by 464
Kenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M., & Raisz, L. G. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.5.m266 · Cited by 456
Vermeulen, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.5.1821 · Cited by 455
Caminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444 · cited 2×
“09 Caminiti, 2009 (22) Injection 2/35 1/35 2.”
ResultMalkin, C. J., Pugh, P. J., West, J. N., van Beek, E. J. R., Jones, T. H., & Channer, K. S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi443 · Cited by 413
Androgen Treatment of Abdominally Obese Men
Mårin, P., Holmtäng, S., Gustafsson, C., Jönsson, ‡., Kvist, ‡., Elander, A., Eldh, J., Sjöström, L., Holm, G., & Björntorp, P. (1993) · Obesity Research · doi:10.1002/j.1550-8528.1993.tb00618.x · Cited by 345
Trends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336 · cited 1×
“While US testosterone prescriptions have tripled in the past decade (9), debate continues over the risks and benefits of TRT.”
BackgroundSinha-Hikim, I., Cornford, M., Gaytan, H., Lee, M. L., & Bhasin, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0357 · Cited by 318 · cited 1×
“At higher doses, T also stimulates muscle protein synthesis via a number of mechanisms that include proliferation of muscle satellite cells and donation of their nuclei to the myofibril (71), elevation of muscle IGF-I (69), and activation of the Akt/4 mammalian target of rapamycin (mTOR) pathway (90).”
BackgroundCorona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297 · cited 1×
“(25) have published a new meta-analysis of 75 studies, assessing the CV risks of TRT, using less stringent inclusion criteria than our study and that of Xu et al.”
BackgroundTracz, M. J., Sideras, K., Boloña, E. R., Haddad, R. M., Kennedy, C. C., Uraga, M. V., Caples, S. M., Erwin, P. J., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0036 · Cited by 275 · cited 2×
“In older men, T increases BMD in regions that have a large component of cancellous bone, such as the lumbar spine and hip (84).”
BackgroundMeier, C. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.2 · Cited by 274 · cited 1×
“In older men, low serum T is associated with osteopenia (49) and increased fracture risk (55).”
BackgroundHandelsman, D. J. (2013) · Medical Journal of Australia · doi:10.5694/mja13.10111 · Cited by 253 · cited 1×
“T use in the United States increased more than threefold between 2000 and 2011 (36).”
BackgroundAndrogen Treatment and Muscle Strength in Elderly Men: A Meta‐Analysis
Ottenbacher, K. J., Ottenbacher, M. E., Ottenbacher, A. J., Acha, A. A., & Ostir, G. V. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2006.00938.x · Cited by 173 · cited 1×
“(60), assessing 11 RCTs of TRT in older men, reported that injected TRT produced a “moderate” increase in muscle strength, whereas the effects of transdermal and oral TRT were much less.”
BackgroundSpitzer, M., Basaria, S., Travison, T. G., Davda, M. N., Paley, A., Cohen, B., Mazer, N. A., Knapp, P. E., Hanka, S., Lakshman, K. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00004 · Cited by 163
Svartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160 · cited 2×
“88 Svartberg, 2008 (78) Injection 1/19 0/19 3.”
ResultBhasin, S., Travison, T. G., Storer, T. W., Lakshman, K., Kaushik, M., Mazer, N. A., Ngyuen, A.-H., Davda, M. N., Jara, H., Aakil, A., et al. (2012) · JAMA · doi:10.1001/jama.2012.227 · Cited by 152
Hildreth, K. L., Barry, D. W., Moreau, K. L., Vande Griend, J., Meacham, R. B., Nakamura, T., Wolfe, P., Kohrt, W. M., Ruscin, J. M., Kittelson, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3695 · Cited by 140 · cited 2×
“46 Hildreth, 2013 (37) Gel 3/96 10/47 0.”
BackgroundMorris, P., Malkin, C., Channer, K., & Jones, T. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510241 · Cited by 122 · cited 1×
“However, serum bioT may be estimated from serum total T, SHBG, and albumin by using one of several empirical formulas (57, 86).”
MethodHoyos, C. M., Killick, R., Yee, B. J., Grunstein, R. R., & Liu, P. Y. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04413.x · Cited by 118 · cited 2×
“(39), who treated middle-aged men who had severe obstructive sleep apnea with T.”
BackgroundBorst, S. E., Yarrow, J. F., Conover, C. F., Nseyo, U., Meuleman, J. R., Lipinska, J. A., Braith, R. W., Beck, D. T., Martin, J. S., Morrow, M., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00592.2013 · Cited by 98 · cited 9×
“In our study of one year of im TRT in older men, T alone caused a 40% increase in prostate volume, whereas T plus finasteride produced the same musculoskeletal benefits as T alone but with no prostate enlargement (19).”
BackgroundResultSelf-citationEfficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men
Kaufman, J. M., Miller, M. G., Garwin, J. L., Fitzpatrick, S., McWhirter, C., & Brennan, J. J. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02265.x · Cited by 70 · cited 1×
“90 Kaufman, 2011 (44) Gel 11/234 0/40 4.”
Ho, C. C. K., Tong, S. F., Low, W. Y., Ng, C. J., Khoo, E. M., Lee, V. K. M., Zainuddin, Z. M., & Tan, H. M. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10755.x · Cited by 53 · cited 1×
“21 Ho, 2012 (38) Injection 1/60 1/60 1.”
Kaplan, A. L., & Hu, J. C. (2013) · Urology · doi:10.1016/j.urology.2013.03.049 · Cited by 42
Cited by
Skeletal muscle aging: influence of oxidative stress and physical exercise
Gomes, M. J., Martinez, P. F., Pagan, L. U., Damatto, R. L., Mariano Cezar, M. D., Ruiz Lima, A. R., Okoshi, K., & Okoshi, M. P. (2017) · Oncotarget · doi:10.18632/oncotarget.14670 · Cited by 285
“Other studies have also suggested that testosterone increases muscle mass and power [127, 129].”
BackgroundThe role of Toll-like receptors and neuroinflammation in Parkinson’s disease
Heidari, A., Yazdanpanah, N., & Rezaei, N. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02496-w · Cited by 275
“DHT is an injectable drug that can penetrate the BBB and affect the CNS as it has a lipophilic molecular structure [127, 128].”
BackgroundMuscle wasting and aging: Experimental models, fatty infiltrations, and prevention
Brioche, T., Pagano, A. F., Py, G., & Chopard, A. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.04.006 · Cited by 129
Clomiphene Citrate for the Treatment of Hypogonadism
Wheeler, K. M., Sharma, D., Kavoussi, P. K., Smith, R. P., & Costabile, R. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.10.001 · Cited by 81
Skinner, J. W., Otzel, D. M., Bowser, A., Nargi, D., Agarwal, S., Peterson, M. D., Zou, B., Borst, S. E., & Yarrow, J. F. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12291 · Cited by 76
Self-citation
Metadata
- Authors
- Borst, S. E., & Yarrow, J. F.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2015-06-15
- Volume
- 308
- Issue
- 12
- Pages
- E1035-E1042
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W1988683927
- Cited by
- 62
- References
- 43
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.